Avedro to Present Research on Proprietary Corneal Cross-Linking Technologies at 2019 ARVO Annual Meeting
The presentations include data on technologies relating to Avedro’s proprietary Epi-On (epithelial-on) and PiXL corneal cross-linking procedures. Avedro’s Epi-On procedure is designed to treat the cornea without the need to remove the epithelium and is currently being studied in a U.S. pivotal Phase 3 clinical trial for the treatment of progressive keratoconus, a debilitating and typically progressive eye disease that, if left untreated, can lead to loss of vision and even blindness. The PiXL procedure is in development to non-invasively improve vision for patients with presbyopia, the normal loss of near focusing ability that occurs with age, which we estimate affects more than 50 million people in
“Avedro is committed to developing important new technologies for corneal cross-linking as we pursue next-generation solutions for vision loss,” said Reza Zadno, PhD, President and Chief Executive Officer of
The scientific poster presentations are scheduled as follows:
8:00-9:45 AM– Biomechanical Impact of Drug Formulation, Supplemental Oxygen, and UV Delivery on Epi-On CXL. Adler DC, Hill J, Liu C, Deardorff P, Raizman M, Rajpal R. Poster#317-B0509.
8:00-9:45 AM– Stromal Oxygen Dynamics During High-Irradiance Epi-On Corneal Crosslinking. Hill J, Liu C, Deardorff P, Thompson V, Gore D, Adler DC. Poster #325-B0517.
8:00-9:45 AM– Impact of Eye Motion and Active vs. Passive Eye Tracking on Refractive Crosslinking. Usher D, Mukherjee A, Smirnov M, Hill J, Eddington W, Liu C, Adler DC. Poster #327-B0519.
|Avedro Contact:||Investor Contact:|
|David Iannetta||Greg Chodaczek or Lynn Lewis|
|Phone: 781-768-3400||Phone: 646-924-1769|
Source: Avedro, Inc